Risk of Pancreatic cancer in Individuals With Celiac Disease in the United States: A Population-Based Matched Cohort Study SUPPLEMENTARY METHODS

Data source:

TriNetX (Cambridge, MA) Research Network uses electronic health record(EHR) data collected from member healthcare organizations (HCOs) in the United States^[1]. HCO is a large academic health center with data from most of its affiliates. TriNetX's cloud-based feature allows real-time access to de-identified clinical data and analytical tools. Act-compliant, longitudinal clinical data to member HCOs is provided on a cloud-based platform. All clinical data is de-identified and aggregated directly from the EHR of participating HCOs. A typical organization has a complex enterprise architecture where the data flow through several different databases, such as a data warehouse and a research data repository, in addition to EHR data available in a structured fashion (e.g., demographics, diagnoses, and laboratory test results).

Standardizing the terminology (mapping codes) and data quality check:

TriNetX has production capabilities that have been tested that map data extensively from each of these structures to the standard model within TriNetX and can extract facts of interest from the narrative text of clinical documents using natural language processing. TriNetX maps the data to a standard and controlled set of clinical terminologies, enforces a list of required fields (e.g., patient identifier), and rejects those records where the required information is missing. As the data are refreshed, the software monitors changes in volumes of data over time to ensure data validity.

Clinical fact and coding system to present Data:

TriNetX has a team of informaticists who map data from the data provider's local codes to master terminology within TriNetX. Laboratory test results, vitals, and findings are coded to logical observation identifiers names and codes (LOINC). Demographics are health level 7 (HL7), version 3 (administrative standards), and Diagnoses are represented by the International Classification of Diseases, Ninth and 10th Revisions, Clinical Modification (ICD-9-CM and ICD-10-CM), and diagnoses data

are enriched with the chronic condition indicator. Depending on the coding system used by an HCO, procedure data are coded in current procedural terminology (CPT) or ICD-10 Procedure Coding System.

Definition of study variables:

We defined Coeliac disease with the following inclusion criteria: ICD-10 codes of K90.0 (Celiac disease). Pancreatic cancer ICD-10: C25.X

Selection of patients with non-CD cohort:

We excluded the patients if they had a diagnosis of CD based on the abovementioned codes that we used to select patients in the non-CD cohort.

Supplementary Figure 1:

Figure 1A. Propensity score density graph before and after matching among CD patients (purple) and Non-CD controls (blue).



	Before		prop	After propensity matching							
Variables	matching										
	Celiac		Non-CD	SM	Celiac		Non-CD		SMD		
	disease		controls	D	disease		controls				
	(N=1558		(N=23410				(N=13468				
	77)		3)		(N=134	6	0)				
					80)						
Gliadin antibodies, mean ± SD											
Serum Gliadin peptide	22.1	±	7.75 ±	0.54	21 ± 33		8.63 ± 19	9	0.459		
IgA Ab [Units/volume]	33.6		16.1	29					1		
by Immunoassay											
Serum Gliadin IgG Ab	15.6	±	4.94 ±	0.72	15.1	±	5.47	±	0.633		
[Units/volume] by	17.8		6.09	76	17.4		7.02		6		
Immunoassay											
Metabolic profile, mean ± SD											
HbA1C	6.47	±	6.22 ±	0.12	6.31	±	6.24	±	0.032		
	2.07		1.78	67	1.95		1.89		2		
Blood glucose (mg/dL)	104	±	105 ± 38.9	0.01	103	±	103 ± 37	.4	0.005		
	50.2			40	47.9				8		
Creatinine (mg/dL)	0.815	±	1.01 ±	0.11	0.833	±	0.927	±	0.066		
	1.22		2.05	43	1.11		1.68		1		
Total protein (g/L)	6.97	±	7.08 ±	0.09	6.97	±	7.04	±	0.061		
	1.05		1.16	36	1.04		1.21		2		
BUN (mmol/L)	13.6	±	15.8 ±	0.24	13.8	±	15.2 ± 9.	5	0.169		
	7.04		10.5	65	7.1				0		
Digestive enzymes, <i>mean</i> ± <i>SD</i>											
Serum lipase (U/L)	70.5	±	70.8 ± 302	0.00	66.2	±	69.2 ± 22	24	0.006		

Supplementary Table 1: Laboratory findings of the study cohort

	714				05	629				4		
Serum amylase (U/L)	66.3	±	70.3	±	0.04	65.6	±	66.5	±	0.012		
	92.8		89.2		37	68.7		75.2		4		
Inflammatory markers, mean ± SD												
CRP(mg/L)	11 ± 2	9.1	16.9	±	0.17	11.1	±	15.8	±	0.143		
			37.4		52	29.7		35.6		9		
ESR(mm/h)	16.3	±	23.7	±	0.34	17 ± 1	8.9	20.7	±	0.185		
	18.4		23.8		78			21.7		3		
Lipid profile, mean ± SD												
CH(mg/dL)	177	±	179 ± 4	44.5	0.03	178	±	179 ± 4	3.7	0.026		
	43.8				92	43.8				5		
TG(mg/dL)	121	±	130 ± 9	95.8	0.09	122	±	129 ±	99	0.075		
	97.5				37	97.7				3		
LDL(mg/dL)	102	±	102 ± 3	36.5	0.00	102	±	102 ± 3	5.7	0.014		
	35.2				07	35.2				7		
HDL (mg/dL)	51.8	±	51.4	±	0.01	51.8	±	51.9 ±	20	0.005		
	19.6		19.6		93	19.7				9		
Others, mean ± SD												
Hemoglobin (g/dL)	13.1	±	12.8	±	0.16	13.1	±	12.9	±	0.088		
	1.84		2.07		64	1.86		1.98		4		
НСТ (%)	39.3	±	38.5	±	0.13	39.3	±	38.8	±	0.091		
	5.21		5.99		23	5.26		5.78		0		
Serum Calcium	9.27	±	9.27	±	0.00	9.26	±	9.29	±	0.040		
	0.64		0.609		33	0.637		0.596		8		

Abbreviations: CD, celiac disease; SD, standard deviation; Ad, antibodies; HbA1C, Hemoglobin A1C; BUN, blood urea nitrogen; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; CH, cholesterol; TG, total cholesterol; LDL, lowdensity lipoprotein; HDL, high-density lipoprotein; HCT, hematocrit.

Reference:

^{1 .} TriNetX: Longitudinal Real World Data. TriNetX; 2021. Available at: https://www.trinetx.com/trinetx-research.